{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Upenazime is a non-radioactive chemical precursor for diagnostic imaging.
Status:
Investigational
Source:
NCT04307953: Phase 2 Interventional Recruiting Fibrodysplasia Ossificans Progressiva
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Saracatinib (AZD0530) is an oral, dual inhibitor of c-Src/Abl kinases initially developed by AstraZeneca for the treatment of cancer. The drug was tested for many neoplasms and reached phase III for ovarian cancer (in combination with paclitaxel), however without demonstrating any significant effect. Sarcatinib is also tested in patients with Alzheimer's Disease (Phase II). Its effect on Alzheimer's Disease patients is explained by inhibition of another kinase, Fyn, which is highly expressed in brain.
Status:
Investigational
Source:
NCT01435096: Phase 1 Interventional Completed Malignant Solid Tumour
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Elomotecan (BN 80927), a homocamptothecin derivative, inhibits both topoisomerase I and topoisomerase II mediated DNA relaxation. It potently inhibits proliferation of human tumor cells in vitro and in vivo. Elomotecan was being developed for the treatment of solid tumors.
Status:
Investigational
Source:
NCT00244751: Phase 2 Interventional Completed Cirrhosis, Liver
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Farglitazar is a non-thiazolidinedione insulin sensitizer and agonist of peroxisome proliferator-activated receptor-gamma. GlaxoSmithKline was developing farglitazar for the treatment of liver fibrosis and Type 2 diabetes mellitus.
Class (Stereo):
CHEMICAL (ACHIRAL)
Metoxepin was developed as an antiemetic, neuroleptic and antihistamine agent. This drug has never been marketed.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cefedrolor is a broad-spectrum cephalexin antibiotic patented by pharmaceutical company Bristol-Myers Co.
Status:
Investigational
Source:
NCT00486876: Phase 2 Interventional Completed Irritable Bowel Syndrome
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Dextofisopam, a non-serotonergic agent currently being evaluated for the treatment of irritable bowel syndrome (IBS), is the R-enantiomer of racemic tofisopam, a molecule marketed and used safely outside the United States for over three decades for multiple indications including IBS. Dextofisopam represents a novel, first-in-class opportunity with a positive proof-of-concept study in an arena where there are few compounds with unique approaches or positive efficacy results. By structure, Dextofisopam is a member of the homophthalazine class; Dextofisopam binds to specific receptors in areas of the brain affecting autonomic function, including gastrointestinal (GI) function. Unlike the two 5-HT3 or 5-HT4 mediated IBS therapies currently available, both with significant safety concerns, Dextofisopam novel non-serotonergic activity offers a unique and innovative approach to IBS treatment. Recent studies have indicated that
dextofisopam binds to a novel binding site within the
central nervous system that may be responsible for
mediating its actions. This receptor has been characterized
as the 2,3-benzodiazepine receptor, which is
distinct from the classical 1,4 or 1,5-benzodiazepine
receptor. Dextofisopam has no significant binding at
other receptors or ion channels
Status:
Investigational
Source:
NCT01817959: Phase 3 Interventional Completed Islet Transplantation in Diabetes Mellitus Type 1
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Reparixin is a CXC chemokine receptor type 1 (CXCR1) and type 2 (CXCR2) inhibitor. This compound has potential antineoplastic activity. It can be administered orally, binds to CXCR1 (overexpressed on cancer stem cells) and prevents its activation by its ligand interleukin 8. This might result in the death of cancer cells and inhibition of cell progression and metastasis. Reparixin also inhibits CXCR2 activation, possibly reducing both neutrophil recruitment and vascular permeability during inflammation or injury. A phase II clinical trial evaluating the effects of orally administered reparixin on cancer stem cells in the primary tumor and the tumoral microenvironment in an early breast cancer population was terminated. Reparixin has also been suggested as a novel potential therapeutic strategy for aggressive forms of thyroid cancer, based on results of a xenotransplantation study in mice.
Status:
Investigational
Source:
INN:inixaciclib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (RACEMIC)
Ciglitazone, 5-[4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4-dione, is a hypoglycemic agent and a thiazolidenedione derivative. Ciglitazone binds to the PPAR gamma receptor and possesses agonist activity. This drug was in clinical trials in Japan for the treatment Diabetes mellitus, but that study has been discontinued. Ciglitazone was able to decrease the production of vascular endothelial growth factor (VEGF) in an in vitro human granulosa cell model. That result together with the pivotal role of VEGF in ovarian hyperstimulation syndrome suggests that ciglitazone may have a high potential as a therapeutic agent.
